Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Published on 25/02/202525/02/2025 by Top Pharmaceutical

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology 🧪. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) 📚. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. 🎓🔬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine 🏥. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant 📖. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies 🔬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) 🏥. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine 🔬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology 📚.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate 📚, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers 🔬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors 🏅. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology 🧠💊, medicinal chemistry ⚗️, and molecular neuroscience 🔬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems 🚀, enantiomeric drug behavior 🔄, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.

Publication Top Notes

Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers

Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif

Synthesis and Properties of a Water-Soluble Ureide Derived from Gаlodif and Succinic Acid

A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers

Effect of original anticonvulsant ortho-fluoro-benzonal on immune cells functional properties at chronic ethanol intoxication

The original anticonvulsant meta-Cl-benzhydrylurea (m-CL-BHM) induces of the liver monooxygenase system and stimulates the neuroimmune response in behavioral disorders of alcoholic origin

EMBRIOGENESIS OF NEURONAL ELENENTS (GLIOBLASTS AND GABAA RECEPTORS) IN THE HUMAN BRAIN NEUROIMMUNE SYSTEM UNDER PRENATAL ALCOHOL EXPOSURE

An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism

Pranab Das | Bioinformatics in Pharmaceuticals | Best Scholar Award

Published on 24/02/202524/02/2025 by Top Pharmaceutical

Pranab Das | Bioinformatics in Pharmaceuticals | Best Scholar Award

Mr Pranab Das, NIT Nagaland, India

Pranab Das is an Assistant Professor in the Department of Computer Science at Kumar Bhaskar Varma Sanskrit and Ancient Studies University, Assam. He holds an M.Tech in Computer Science from NIT Meghalaya and has submitted his Ph.D. thesis at NIT Nagaland. His research focuses on computational biology, drug discovery, and machine learning 🧬🤖. With multiple SCIE and SCI-indexed publications in top journals, he has made significant contributions to predicting drug functions and adverse reactions. Additionally, he has presented at international conferences and authored book chapters 📚. He has qualified JRF, NET, and SLET, showcasing his academic excellence.

Publication Profile

orcid

Education

Pranab Das is a dedicated researcher in Computer Science and Engineering (CSE), currently awaiting the completion of his Ph.D. (2021-2024) from the National Institute of Technology (NIT) Nagaland, where he achieved an impressive 9.23 CGPA 🎓. He holds an M.Tech in CSE (2019-2021) from NIT Meghalaya with a 9.27 CGPA 🏆 and a BE in CSE (2015-2018) from Jorhat Engineering College, securing 73.89% 📚. His academic journey began with a Diploma (70%) from Assam Engineering Institute and 10th grade (66.17%) from Barnibari Milan High School. Additionally, he has cleared JRF, NET, and SLET 🔬✅.

Project Work

Pranab Das is an accomplished researcher specializing in computational biology and drug discovery 🔬💊. His latest work, “MLCNNF: A Multi-Label Convolutional Neural Network Framework for Predicting Adverse COVID Drug Reactions”, is published in IEEE Transactions on Computational Biology and Bioinformatics (2025) 📄. He has also co-authored “BRMCF: Binary Relevance and MLSMOTE-Based Computational Framework” (2022) and “Advances in Predicting Drug Functions” (2023). His research extends to machine learning applications in pharmacology, including drug classification and side-effect prediction 🧠📊. With publications in high-impact journals (IF: 2.4-23.8) 📈, Pranab contributes significantly to AI-driven drug discovery 🚀.

Area of Intrest

Pranab Das is deeply passionate about cutting-edge technologies in Artificial Intelligence (AI) 🤖, Machine Learning (ML) 📊, and Deep Learning (DL) 🧠, with a strong focus on their applications in Bioinformatics 🔬. His research explores innovative AI-driven solutions for drug discovery, predictive modeling, and computational biology. By leveraging ML and DL techniques, he aims to enhance drug function prediction, side-effect analysis, and disease modeling. His interdisciplinary approach bridges technology and life sciences, driving impactful advancements in healthcare and pharmaceuticals 💊. Pranab continues to push the boundaries of AI in biomedical research, shaping the future of intelligent drug discovery 🚀.

Research Focus

Pranab Das is a researcher specializing in computational biology, bioinformatics, and artificial intelligence in drug discovery 🧬💻. His work primarily focuses on predicting drug functions, adverse drug reactions, and drug-disease associations using multi-label machine learning and deep neural networks 🤖🧪. He has contributed extensively to the field through innovative frameworks like MLCNNF, K1K2NN, and BRMCF, integrating chemical structures, gene ontology, and biological properties for enhanced drug prediction accuracy 🏥🔬. His research advances COVID-19 drug safety, pharmacology, and computational chemistry, making significant contributions to the intersection of AI and healthcare 🏥📊.

Publication Top Notes

MLCNNF: A Multi-Label Convolutional Neural Network Framework for Predicting Adverse COVID Drug Reactions From the Chemical Structure

A novel neural network-based nearest neighbor approach for drug function prediction from chemical structures

BRMCF : Binary Relevance and MLSMOTE based Computational Framework to Predict Drug Functions from Chemical and Biological Properties of Drugs.

A Comprehensive Survey of Studies on Predicting Anatomical Therapeutic Chemical Classes of Drugs

Inceptionv3‐LSTM‐COV: A multi‐label framework for identifying adverse reactions to COVID medicine from chemical conformers based on Inceptionv3 and long short‐term memory

K1K2NN: A novel multi-label classification approach based on neighbors for predicting COVID-19 drug side effects

Advances in Predicting Drug Functions: A Decade-Long Survey in Drug Discovery Research

An Extensive Survey on the Use of Supervised Machine Learning Techniques in the Past Two Decades for Prediction of Drug Side Effects

MLCNN‐COV: A multilabel convolutional neural network‐based framework to identify negative COVID medicine responses from the chemical three‐dimensional conformer

Ali Raza | Nanomedicine | Best Researcher Award

Published on 24/02/202524/02/2025 by Top Pharmaceutical

Ali Raza | Nanomedicine | Best Researcher Award

Mr Ali Raza, Minhaj University Lahore, Pakistan

Ali Raza is a dedicated mathematician with an M.Phil in Applied Mathematics from the University of Engineering and Technology, Lahore. His research focuses on fractional calculus, fluid dynamics, and mathematical modeling. His M.Phil thesis explored magnetohydrodynamics convection fluid flow using Atangana-Baleanu fractional derivatives. As a reviewer for prestigious international journals, he has significantly contributed to the field. With numerous high-impact publications, Ali Raza continues to advance numerical solutions for complex differential equations, enhancing scientific understanding in thermal engineering and mechanics. 📚✨

Publication Profile

Scopus

Education

Ali Raza 🎓 is a dedicated mathematician with a strong academic background in applied mathematics. He earned his M.Phil in Applied Mathematics from the University of Engineering and Technology, Lahore (2019–2021) 📊, where he honed his analytical and problem-solving skills. Prior to that, he completed his B.S. (Hons) in Mathematics at the University of Gujrat, Pakistan (2013–2018) ➗, building a solid foundation in mathematical theories and applications. His passion for numbers and logical reasoning has driven him to excel in the field, contributing to advanced research and innovative solutions in mathematics. 🔢✨

Research Interests

Ali Raza 🔢 is deeply passionate about advanced mathematical concepts and their real-world applications. His research interests include Fractional Calculus 📐, where he explores complex mathematical structures, and Fluid Dynamics 🌊, focusing on the movement of liquids and gases. He is also engaged in the Numerical Solution of PDEs 🖥️, utilizing computational methods to solve complex equations. His expertise extends to Mechanics ⚙️, Mathematical Modelling 📊, and Differential Equations and Transforms 🔄, contributing to innovative problem-solving in science and engineering. Through his research, Ali aims to develop efficient mathematical techniques to tackle real-world challenges.

Work Experience

Ali Raza 🎓 has valuable teaching experience as a Lecturer of Mathematics, shaping young minds with his expertise. He began his career at the Sialkot College of Technology (2017–2018) 📐, where he taught advanced mathematical concepts and problem-solving techniques. He then joined the Punjab Group of Colleges, Zafarwal (2018–2019) 🏫, further refining his teaching methods and inspiring students with his passion for mathematics. His dedication to education, coupled with his strong analytical skills, has made a significant impact on his students. Ali continues to contribute to the academic field, fostering a love for mathematics among learners. 🔢✨

Research Focus

Ali Raza’s research primarily focuses on geopolymer concrete, sustainable construction materials, and composite materials 🏗️🌱. His work explores the mechanical, microstructural, and thermal properties of innovative cementitious materials, including fly ash, metakaolin, recycled aggregates, graphene-based composites, and nanomaterials 🔬⚙️. He has contributed to advancements in low-carbon concrete, fiber-reinforced composites, and self-compacting concrete for enhanced durability and sustainability 🌍. His studies also extend to heat transfer analysis in nanofluids and structural retrofitting with eco-friendly materials 🏢🔥. His research is instrumental in developing high-performance, environmentally friendly alternatives for modern construction technologies 🚀.

Publication Top Notes

Combined effects of elevated temperature, sulfates and chlorides on performance of fly ash and metakaolin-based recycled aggregate geopolymer concrete

Microstructural and thermal characterization of polyethylene and basalt fiber-reinforced natural zeolite-based engineered geopolymer composites

Mechanical and microstructural characteristics of fly ash-based concrete having copper-zinc oxide and graphitic carbon nitride hybrid composites

Fractional analysis for heat consumption of CuO-based hybrid nanofluid via integral transform

Mechanical and microstructural characterization of molybdenum tailings-, GGBS- and recycled aggregate based-low carbon self-compacting concrete

Material characterization of high-ductility geopolymer composites developed with industrial and construction & demolition wastes

Mechanical strength and mineralogical properties of fiber-reinforced geopolymer composites with multi-walled carbon nanotubes

Mechanical and microstructural characterization of recycled aggregate geopolymer concrete having high strength and recycled tire steel wire fibers

Performance of retrofitted eccentrically loaded GFRP-reinforced electronic waste concrete components having synthetic fibers

Zeynep Kalaycıoğlu | Pharmaceutical Chemistry | Best Researcher Award

Published on 24/02/202524/02/2025 by Top Pharmaceutical

Zeynep Kalaycıoğlu | Pharmaceutical Chemistry | Best Researcher Award

Assoc. Prof. Dr Zeynep Kalaycıoğlu, Istanbul Technical University, Turkey

Assoc. Prof. Dr. Zeynep Kalaycıoğlu is a distinguished researcher and lecturer at Istanbul Technical University 🏛️, specializing in analytical chemistry 🧪. Her expertise spans metal/metal oxide nanoparticle synthesis, drug-protein interactions, and biopolymeric composite films for food packaging and wound dressing 🌱. With over 30 high-impact publications 📄, two book chapters 📚, and multiple research projects, she has significantly contributed to multidisciplinary collaborations in materials science, biochemistry, and pharmaceutical sciences 🏆. Currently, she leads a funded project on green synthesis of bioactive nanoparticles from olive mill wastewater 🌿, promoting sustainability in scientific innovation. 🚀

Publication Profile

Scopus

Professional Background

Assoc. Prof. Dr. Zeynep Kalaycıoğlu is an academic researcher and lecturer at Istanbul Technical University, specializing in analytical chemistry 🔬. Her Ph.D. focused on isolating and characterizing bioactive compounds from natural products 🌿, developing advanced analytical techniques, and exploring biopolymer applications. With extensive experience in teaching analytical chemistry labs 🏫, she has guided students through complex experimental techniques. Her research interests span metal/metal oxide nanoparticle synthesis ⚛️, drug-protein interactions 💊, and biopolymeric composite films. Dr. Kalaycıoğlu collaborates with multidisciplinary teams across materials science, biochemistry, and pharmaceutical sciences, contributing to cutting-edge advancements in her field 🔍.

Professional Memberships

Assoc. Prof. Dr. Zeynep Kalaycıoğlu is a dedicated member of the Turkish Chemical Society ⚗️ and an expert in analytical chemistry 🔬. Her research focuses on metal/metal oxide nanoparticle synthesis ⚛️, drug-protein interactions 💊, and biopolymeric composite films for food packaging 🥫 and wound dressing 🩹. She also specializes in capillary electrophoresis, statistical analysis 📊, food analysis 🍎, and water remediation 💧. Additionally, her work involves molecular docking 🧬 to explore chemical interactions at the molecular level. Through her multidisciplinary research, Dr. Kalaycıoğlu continues to contribute innovative solutions to chemistry, materials science, and pharmaceutical applications.

Academic Research

Assoc. Prof. Dr. Zeynep Kalaycıoğlu actively shares her research through various academic platforms 🌐. Her profiles on Google Scholar 📚, ResearchGate 🔬, and LinkedIn 💼 showcase her contributions to analytical chemistry and multidisciplinary studies. These platforms highlight her publications, collaborations, and scientific impact. Additionally, she maintains a repository of relevant ID and certification documents 🏆, ensuring transparency and credibility in her academic journey. By engaging with global researchers and institutions, Dr. Kalaycıoğlu continues to advance knowledge in nanoparticle synthesis, drug-protein interactions, and biopolymeric applications, making significant contributions to science and technology.

Awards

Assoc. Prof. Dr. Zeynep Kalaycıoğlu is honored to be considered for prestigious scientific awards 🏆. With her extensive contributions to analytical chemistry, nanoparticle synthesis ⚛️, and biopolymeric applications 🌿, she aligns with categories such as the Distinguished Scientist Award, Outstanding Scientist Award, and Excellence in Research 🔬. As a dedicated educator and innovator, she also qualifies for the Best Faculty Award 🎓 and Best Innovation Award 💡. Passionate about advancing science and mentoring future researchers, she seeks recognition that reflects her commitment to groundbreaking discoveries and impactful contributions to multidisciplinary research.

Research Focus

Assoc. Prof. Dr. Zeynep Kalaycıoğlu’s research primarily focuses on biophysical chemistry 🧪, particularly the interaction of biomolecules 🧬 with pharmaceutical and polymeric compounds. Her work spans protein-ligand binding 🔬, spectroscopic characterization 📊, and molecular docking analysis 🖥️ to understand biochemical interactions at a molecular level. She also explores nanomaterials ⚛️ for biomedical applications, including wound healing hydrogels 🩹 and drug delivery systems 💊. Her expertise in capillary electrophoresis ⚡ further enhances the understanding of biomolecular interactions. Through her interdisciplinary approach, she contributes to advancements in biomedical engineering 🏥, materials science 🏗️, and pharmaceutical research 🌱.

Publication Top Notes

Binding interaction between sodium carboxymethyl cellulose and serum albumin: Insights from multi-spectroscopy methods, rheological characterization and molecular docking analysis

Foam-based antibacterial hydrogel composed of carboxymethyl cellulose/polyvinyl alcohol/cerium oxide nanoparticles for potential wound dressing

Capillary Electrophoresis-Frontal Analysis (CE-FA) and Molecular Docking Studies on the Albumin-Binding Properties of Dopamine and Serotonin

Minahil Khalid | Nanomedicine | Best Researcher Award

Published on 22/02/202522/02/2025 by Top Pharmaceutical

Minahil Khalid | Nanomedicine | Best Researcher Award

Mrs Minahil Khalid, The Women University Multan, Pakistan

Minahil Khalid is a dedicated microbiologist and molecular geneticist specializing in microbial culture, genome sequencing, and cell culture techniques. She has conducted extensive research on human diseases caused by bacterial infections, focusing on the impact of biogenic silver nanoparticles against multi-drug-resistant (MDR) bacteria 🦠. Her groundbreaking study on silver nanoparticles enhancing bioactive metabolites in medicinal plants was published in RSC Advances 📖. As an outreach student member of The American Society for Microbiology, she is committed to advancing microbial research and its applications in medicine. Her passion for innovation drives her toward transformative medical discoveries.

Publication Profile

Scopus

Academic and Professional Background

Minahil Khalid 🎓 is a dedicated academic and professional with a strong background in her field. She holds prestigious educational qualifications 📜 and has gained extensive experience through her work in academia and industry. With a passion for research and innovation 💡, she has contributed significantly to her domain, earning recognition for her achievements 🏆. Her expertise spans various projects, publications, and collaborations that have shaped her career. Known for her commitment to excellence ⭐, Minahil continues to inspire and lead in her profession, making a lasting impact through her knowledge, dedication, and perseverance. 🚀

Professional Memberships

Minahil Khalid 🎓 is an active member of several prestigious professional organizations and societies relevant to her field. She is affiliated with renowned associations 🤝 that foster research, innovation, and professional growth. Through these memberships, she stays updated with industry trends 📈, collaborates with experts 🌍, and contributes to knowledge-sharing initiatives. Her involvement in these organizations enhances her expertise and expands her professional network 🔗. Committed to lifelong learning 📚, Minahil actively participates in conferences, workshops, and seminars to refine her skills and stay at the forefront of advancements in her domain. 🚀

Research and Innovations

Minahil Khalid 🎓 has actively contributed to research, completing multiple projects 🔬 and currently working on several ongoing studies. Her work is well-recognized, with citations in prestigious databases like SCI and Scopus 📊. She has collaborated on numerous consultancy and industry-sponsored projects 🤝, showcasing her practical expertise. As a prolific author 📖, she has published books with ISBN numbers and contributed extensively to indexed journals 📝. Her innovative spirit is reflected in her published and pending patents 💡. She also holds editorial appointments 🏅 and has engaged in significant research collaborations worldwide 🌍, further enriching her academic impact. 🚀

Industry Engagement

Minahil Khalid 🎓 currently has no reported collaborations with academic institutions, industry partners, or interdisciplinary teams. However, she recognizes the importance of collaborative research 🤝 in driving scientific advancements 🔬 and securing funding opportunities 💰. Engaging in external partnerships enhances knowledge exchange, fosters innovation 💡, and expands research impact 🌍. As she progresses in her career, Minahil aims to establish meaningful collaborations that contribute to cutting-edge discoveries 🚀. Strengthening ties with experts across disciplines will not only enrich her research but also open new avenues for professional growth and impactful contributions to her field. 📚

Research Focus

Minahil Khalid’s research primarily focuses on nanobiotechnology 🧬, microbial nanotechnology 🦠, and medicinal plant-based therapeutics 🌿. Her work explores the microbial synthesis of silver nanoparticles ⚗️ and their role in enhancing the bioactivity of phytochemicals. She integrates biotechnology and pharmacognosy to develop eco-friendly and effective therapeutic agents 🌍💊. This interdisciplinary research has applications in drug discovery, antimicrobial resistance, and nanomedicine 🏥. Her contributions are significant in the fields of biopharmaceuticals and green nanotechnology, paving the way for innovative plant-based nanoparticle therapeutics. 🌱🔬

Publication Top Notes

Microbial mediated silver nanoparticles enhance the potential of bioactive metabolites in the medicinal plant Linum usitatissimum

Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021

Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on 20/02/202521/02/2025 by Top Pharmaceutical

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr Kanwaljit Rana,Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India, India

Dr. Kanwaljit Rana 🧬📊 is a health researcher specializing in computational biology and big data analytics for disease diagnosis and health outcome prediction. Holding a Ph.D. in Biotechnology from GADVASU, India (2022), Dr. Rana integrates large-scale clinical, biological, and omics data using machine learning for precision medicine. With research experience at ICGEB and PGIMER, he has developed bioinformatics pipelines for genomics and predictive health analytics. His expertise spans AI-driven diagnostics, wearable health tech, and big data automation. A published scientist and GATE-qualified scholar, Dr. Rana continues to innovate in health data science and computational medicine. 🚀

Publication Profile

Google scholar

Education

Dr. Kanwaljit Rana 🎓 holds a Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), India (2022). With a strong academic foundation, he previously earned a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar. His expertise lies in cutting-edge biotechnological research, contributing to advancements in veterinary and animal sciences 🧬🔬. Passionate about innovation and scientific discovery, Dr. Rana continues to explore new frontiers in biotechnology, striving to make a meaningful impact in the field. His dedication to research and development reflects his commitment to scientific excellence and progressive learning

Professional Experience

Dr. Kanwaljit Rana 🎓 is a dedicated Research Associate at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (Feb 2024 – Aug 2024), where he conducts advanced bioinformatics analysis 🧬, integrating genomics and metagenomics data for disease characterization. Previously, at PGIMER, Chandigarh (Sep 2022 – Jan 2023), he developed automated workflows for tuberculosis meningitis diagnosis 🏥. His research journey includes roles at Punjab Agricultural University (PAU), Ludhiana, and Swami Vivekanand Faculty of Technology & Management, specializing in molecular breeding 🌱 and agricultural biotechnology. He is also a QC Freelancer at Cactus Communications since October 2024 ✍️.

Awards

Dr. Kanwaljit Rana 🎓 is a highly accomplished researcher, having qualified GATE Biotechnology in both 2020 and 2022 🏆, showcasing his expertise in the field. His dedication to innovative research earned him the Best Poster Award 🥇 for his work on “Boon of Cow Curd Consumption” at the National Webinar on Cowpathy and Animal Health (2021) 🐄🧪. His contributions to biotechnology and health sciences continue to make a significant impact, blending traditional knowledge with modern scientific advancements. Dr. Rana remains committed to groundbreaking research and advancements in biotechnology and health sciences 🔬📚

Research Focus

Dr. Kanwaljit Rana’s research primarily focuses on computational genomics 🧬, bioinformatics 🖥️, and veterinary genetics 🐶. His work involves biocomputational analysis of microRNAs, genome assembly, and ancestry studies, particularly in indigenous dog breeds like the Gaddi dog. His expertise extends to genome sequencing, phylogenetics, and the application of programming languages like Python, R, and MATLAB for data analysis. His contributions to veterinary science include genetic insights into animal breeding, evolution, and conservation. Through his interdisciplinary approach, Dr. Rana advances animal genomics, computational biology, and veterinary research, impacting both genetic conservation and bioinformatics applications in animal sciences.

Publication Top Notes

Differential Perspectives Between miRNA and lncRNA in Light of Biogenesis and Functions: A Review

Molecular characterization of indigenous dogs through whole genome analysis

Biocomputational identification of microRNAs from indigenous Gaddi dog genome

Introduction to Python, R, and MATLAB

SON DINH PHONG | Gene Therapy | Best Researcher Award

Published on 20/02/202521/02/2025 by Top Pharmaceutical

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection 🧪🔬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals 📚🧑‍🔬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son 🎓 holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. 🏥🔬 With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. 💡👨‍⚕️

Research and Innovations

Dr. Son Dinh Phong 🔬 is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. 🏥 His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. 📊✨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. 🌍💡

Research Contributions

Dr. Son Dinh Phong 🔬 is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis 🧪🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. 🏥 His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. 🔍🧫 Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. 💻💊 With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. 🚀✨

Editorial Appointments

Dr. Son Dinh Phong 🌍🔬 actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. 🧬📖 His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. 🏥✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. 💡🚀

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases 🫀, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery 🖥️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) 🏥, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers 🎗️ and employs computational approaches 🔬 to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations 💊 for complex diseases.

Publication Top Notes

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation

Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1

Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data

Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease

Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis

Prakriti Sharma | Respiratory Pharmacology | Women Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Prakriti Sharma | Respiratory Pharmacology | Women Researcher

Award

Dr Prakriti Sharma, GADVASU, Ludhiana,India

Dr. Prakriti Sharma 🎓🔬 is a biotechnology researcher specializing in cancer immunology and NFAT signaling. She earned her Ph.D. from Guru Angad Dev Veterinary and Animal Sciences University (2022) and has worked as a Project Associate at CSIR-IMTECH, Chandigarh. Her research explores lung inflammation, bioactive molecules, and cancer therapy. She has received multiple awards for her publications on pesticide impact and nanocarrier-based drug delivery. Dr. Sharma has teaching experience and has contributed to leading journals like Journal of Toxicology and iScience. Her expertise spans molecular biology, immunology, and therapeutic innovations. 📚🧬

Publication Profile

orcid

Education

Dr. Prakriti Sharma 🎓 holds a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar (2013) and earned her Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana (June 2022). Her doctoral research focused on Nuclear Factor of Activated T-Cell Signaling during Deltamethrin-Induced Lung Damage 🧬. She has worked as a Project Associate at CSIR-IMTECH, Chandigarh (2022–2024), specializing in cancer immunology and biology 🏥🔬. With a strong background in biotechnology, Dr. Sharma is dedicated to advancing scientific research in immunology and disease mechanisms, contributing to the field with her expertise and innovative approach.

Awards

Dr. Prakriti Sharma 🎓 has received several prestigious awards and honors in her academic journey. She qualified for the GATE Examination in Biotechnology in 2018 🏆 and was selected for the GEFSES-CREATE training program (2019–2020) 🔬. Her research contributions have been recognized with multiple Best Article awards 📝, including “Pesticide Residues in Food”, “Pesticide Usage and Its Impact on Biodiversity”, and “Common Routes of Pesticide Exposure and Its Protective Measures”, published in Agriculture & Food: e-Newsletter 🌿📖. Her dedication to biotechnology and environmental safety continues to make a significant impact in the field.

Teaching Experience

Dr. Prakriti Sharma 🎓 has gained extensive research and teaching experience in biotechnology and agriculture. She completed a three-month dissertation on Diversity and Characterization of Plant Growth-Promoting Rhizobacteria 🌱 at Dolphin PG Institute, Dehradun. She worked as a Project Fellow in the PlaGen scheme at CSIR-IHBT, Palampur (2015–2016) 🧬. Dr. Sharma also served as an Assistant Professor in Agriculture at Swami Vivekanand Faculty of Technology & Management (2017–2018) 📚. Most recently, she was a Project Associate at CSIR-IMTECH, Chandigarh (2022–2024) 🔬, contributing to cancer research through lipid-nanocarrier drug delivery for endocrine tumors.

Research Interests

Dr. Prakriti Sharma 🔬 is actively engaged in cutting-edge research on inflammation and cancer biology. Her work explores the role of the NFAT signaling pathway in lung inflammation 🫁, aiming to uncover mechanisms behind immune responses. She investigates the anti-inflammatory and apoptotic effects of aptamers, nanoparticles, and bioactive molecules in cancer therapy 🧪🎗️. Additionally, she studies key signaling pathways to understand the complex interactions between immune cells and cancer cells 🧬🔍. Through her research, Dr. Sharma strives to develop innovative therapeutic strategies for inflammatory diseases and cancer treatment, contributing to advancements in biomedical science.

Trainings

Dr. Prakriti Sharma 🎓 has actively participated in various national and international training programs and webinars to enhance her expertise in biomedical research. She completed a Seven-Day National Training on Lab Animals in Biomedical Research 🐭🔬 at MAFSU, Parbhani (2021) and attended a workshop on Bio-methodology & Ethical Use of Laboratory Animals at CSIR-IMTECH, Chandigarh (2022) 📚. She also engaged in international webinars on Drug Discovery – New Lead from Old Drugs 💊 (2020), Alternative Therapies to Mitigate Microbial Resistance 🦠 (2021), and Diagnosis of Bacterial Diseases of Livestock 🐄 (2021), contributing to her growing knowledge in biotechnology and healthcare.

Presentations

Dr. Prakriti Sharma 🎓 has actively contributed to scientific conferences through poster presentations and published abstracts. At VIBCON 2022, she presented her research on Upregulation of IL-4 and IL-13 Following Exposure to Deltamethrin 🧬. She also showcased her study on Transcriptomic Analysis of the Lung After Deltamethrin Exposure at the International e-Symposium on Emerging Focus on Immunology 🫁🔬. In IMMUNOCON 2023, she presented findings on Oleuropein’s Role in Modulating Inflammation and Inducing Cancer Cell Apoptosis 🎗️. Through these contributions, Dr. Sharma continues to advance research in immunology, toxicology, and cancer biology.

Research Focus

Dr. Prakriti Sharma’s research focuses on toxicology, nanomedicine, and molecular biology 🧪🔬. Her work explores the effects of environmental toxins on cellular pathways, including NFAT signaling and lung damage 🫁⚠️. She also investigates nanoparticle-based drug delivery for conditions like rheumatoid arthritis 🏥💊 and malaria treatment 🦟🛡️. Additionally, she studies biogenic nanoparticles for antimicrobial applications and their potential in theranostics—combining diagnostics with targeted therapy 🧬🎯. Dr. Sharma’s interdisciplinary research spans pharmacology, biotechnology, and nanoscience, aiming for innovative therapeutic solutions to combat diseases and environmental hazards 🌍💡.

Publication Top Notes

Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation

A Study on Comparative Antioxidant Properties of Mimosa pudica, Vachellia nilotica, Leucas aspera, Phyllanthus niruri, emidesmus indicus and Adhatoda vasica

Disinfectant-like activity of lipopeptide biosurfactant produced by Bacillus tequilensis strain SDS21

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Prof Liangliang Dai, Northwestern Polytechnical University, China

Prof. Liangliang Dai Associate Professor & Assistant Dean, Institute of Medical Research, Northwestern Polytechnical University. With a PhD and MD in Biomedical Engineering and Biology from Chongqing University under Prof. Kaiyong Cai, Prof. Dai’s research focuses on nanomaterials, drug delivery systems, nanosystems, tumor immunotherapy, and antimetabolic therapy. He has led multiple national and provincial research projects and published in top journals like Nature Communications and Advanced Functional Materials. His innovative work bridges nanotechnology and cancer therapy, advancing biomedical science. 🔬🌿

Publication Profile

orcid

Education Background

Prof. Liangliang Dai holds a Ph.D. in Biomedical Engineering 🎓 from the Ministry of Education College of Bioengineering at Chongqing University, where he conducted advanced research under the mentorship of Prof. Kaiyong Cai. His academic journey also includes an MD in Biology 🧬 from the same institution, further solidifying his expertise in bioengineering and biomedical sciences. Guided by Prof. Cai, his studies focused on cutting-edge innovations in the field. With a strong foundation in interdisciplinary research, Prof. Dai continues to contribute to scientific advancements in biomedical engineering and biology, shaping the future of healthcare and biotechnology 🔬.

Hosted Research Project

Prof. Liangliang Dai has led several prestigious research projects 🔬, contributing significantly to biomedical engineering. He has been awarded funding from the National Natural Science Foundation of China 🏅 for multiple projects (52373157, 52003223) and has received the National Science Foundation for Distinguished Young Scholars of Shaanxi Province (S2025-JC-JQ-0228). Additionally, he has played a key role in the Key R&D Programs of Shaanxi Province (2024SF2-GJHX-26, 2022SF-012) and secured support from the Natural Science Foundation of Shaanxi Province (2019JQ-347) and the Young Talent Fund of University Association for Science and Technology (20200302) 🌍.

Research Contributions

Prof. Liangliang Dai has secured multiple prestigious research grants 🏅, including funding from the National Natural Science Foundation of China and the Key R&D Program of Shaanxi Province. His research focuses on advanced drug delivery systems 💊, tumor immunotherapy 🧬, and biomedical nanotechnology 🔬, making significant contributions to the medical research community. These competitive grants reflect his expertise and the high regard for his work in the scientific field. Through pioneering innovations, Prof. Dai continues to push the boundaries of biomedical engineering, striving for breakthroughs that enhance healthcare and therapeutic solutions globally 🌍.

Global Recognition

Prof. Liangliang Dai is a globally recognized researcher 🌍, collaborating with renowned scientists to develop innovative therapeutic strategies 🔬. His groundbreaking work in cancer therapy 🧬 and nanomaterial-based drug delivery 💊 is paving the way for more effective medical treatments. Beyond securing prestigious grants and publishing impactful research, his contributions hold practical significance in biomedical applications, transforming healthcare solutions. With a commitment to advancing science, Prof. Dai’s influence continues to grow, driving innovation and shaping the future of medicine through cutting-edge technologies and interdisciplinary collaborations 🤝.

Innovative Research

Prof. Liangliang Dai’s research is highly interdisciplinary 🔬, blending nanotechnology, immunotherapy, and bioengineering to advance medical science. His groundbreaking work on multifunctional metal-organic frameworks 🏗️, light-activatable antibiosis for infected bone repair 🦴, and tumor microenvironment modulation 🧬 showcases his pioneering role in translational medicine. By enhancing cancer treatment strategies 🎗️ and optimizing drug delivery systems 💊, his studies have a direct impact on healthcare. Through cutting-edge innovations, Prof. Dai is shaping the future of biomedical science, driving transformative solutions that improve patient outcomes and therapeutic effectiveness worldwide 🌍.

Research Focus

Liangliang Dai’s research primarily focuses on nanotechnology and biomedical engineering 🧪🔬, with a particular emphasis on nanosystems for drug delivery, tumor therapy, and environmental applications. His work explores nanoparticles, metal-organic frameworks (MOFs), and photo-responsive materials to develop advanced cancer treatments 🎗️, chemodynamic therapy ⚛️, immune modulation 🛡️, and antimicrobial strategies 🦠. Dai also investigates water purification 💧 and biofilm control to tackle antibiotic resistance. His research bridges materials science 🏗️ and biomedicine to create multifunctional therapeutic nanosystems, advancing precision medicine 🧬 and environmental health 🌍.